Valneva Se Revenue Growth Rates (VALN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Valneva Se  (NASDAQ: VALN)
 

VALN's Revenue Growth by Quarter and Year

Valneva Se's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VALN Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December 195.62
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 51.85
FY 247.47

VALNs Annual Revenue
Valneva Se's Revenue in the fiscal year 2025 $ 195.62 millions
Valneva Se's Revenue in the fiscal year 2024 $ 189.93 millions
Valneva Se's Revenue in the fiscal year 2023 $ 172.16 millions
Valneva Se's Revenue in the fiscal year 2022 $ 404.66 millions
Valneva Se's Revenue in the fiscal year 2021 $ 389.86 millions




VALN Revenue fourth quarter 2025 Y/Y Growth Comment
Valneva Se achieved in the fourth quarter 2025, above Company average Revenue improvement of 2.99% year on year, to $ 195.62 millions.

Looking into fourth quarter 2025 results within Biotechnology & Pharmaceuticals industry 50 other companies have achieved higher Revenue growth. While Valneva Se' s Revenue increase of 2.99% ranks overall at the positon no. 2554 in the fourth quarter 2025.


VALN Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December 2.99 % 10.32 % -57.46 % 3.8 %
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March 45.85 % -1.11 % 46.73 % -12.37 %
FY   9.75 % 8.35 % -51.51 % -

Financial Statements
Valneva Se's fourth quarter 2025 Revenue $ 195.62 millions VALN's Income Statement
Valneva Se's fourth quarter 2024 Revenue $ 189.93 millions Quarterly VALN's Income Statement


VALN Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March -72.7 % -79.35 % -91.12 % -93.72 %
FY (Year on Year)   9.75 % 8.35 % -51.51 % -


Back to VALN Growth rate Comparisons >> Back to VALN Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #51
Healthcare Sector #377
Overall #2554

Revenue Y/Y Growth Statistics
High Average Low
10.32 % -10.09 % -57.46 %
(Dec 31 2022)   (Dec 31 2023)
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #51
Healthcare Sector #377
Overall #2554
Revenue Y/Y Growth Statistics
High Average Low
10.32 % -10.09 % -57.46 %
(Dec 31 2022)   (Dec 31 2023)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Valneva Se's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


VALN's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


VALN's IV. Quarter Q/Q Revenue Comment


Valneva Se's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
Cumulative Revenue 12 Months Ending $ 195.62 $ 189.93 $ 172.16 $ 404.66 $ 0.00
Y / Y Revenue Growth (TTM) 3 % 10.32 % -57.46 % 3.8 % -
Year on Year Revenue Growth Overall Ranking # 1651 # 1811 # 1245 # 0 # 0
Seqeuential Revenue Change (TTM) 3 % 10.32 % -57.46 % 3.8 % -
Seq. Revenue Growth (TTM) Overall Ranking # 1651 # 1811 # 1645 # 0 # 0


Cumulative Revenue growth Comment
Assuming the Valneva Se's fiscal year would have ended in Dec 31 2025, Valneva Se would have reprted above average annual Revenue improvement of 3% year on year, of $ 196 millions.
This marks a slow-down of the companys growth trends and from the 10.32% rise in Dec 31 2024.

In the Healthcare sector 257 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1651, from total ranking in previous quarter at 1811.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 27
Healthcare Sector # 258
Overall # 1651

Revenue TTM Y/Y Growth Statistics
High Average Low
3.8 %
 -26.83 %
-57.46 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 27
Sector # 258
S&P 500 # 1651
Cumulative Revenue growth Comment
Assuming the Valneva Se's fiscal year would have ended in Dec 31 2025, Valneva Se would have reprted above average annual Revenue improvement of 3% year on year, of $ 196 millions.
This marks a slow-down of the companys growth trends and from the 10.32% rise in Dec 31 2024.

In the Healthcare sector 257 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1651, from total ranking in previous quarter at 1811.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 27
Healthcare Sector # 258
Overall # 1651

Revenue TTM Y/Y Growth Statistics
High Average Low
3.8 %
-26.83 %
-57.46 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 27
Sector # 258
S&P 500 # 1651




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
VALN's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Dec 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2025
Align Technology inc 5.19%$ 5.186 millions
Pacira Biosciences inc 5.14%$ 5.137 millions
Illumina Inc 4.98%$ 4.982 millions
Viatris Inc 4.97%$ 4.974 millions
Merck and Co Inc 4.97%$ 4.967 millions
Alcon inc 4.94%$ 4.944 millions
Cytokinetics Incorporated4.89%$ 4.892 millions
Nature s Sunshine Products inc 4.80%$ 4.800 millions
Royalty Pharma Plc4.78%$ 4.775 millions
Enhabit Inc 4.73%$ 4.725 millions
Gilead Sciences Inc 4.70%$ 4.703 millions
Sotera Health Company4.65%$ 4.652 millions
National Healthcare Corp4.65%$ 4.647 millions
Carlsmed Inc 4.63%$ 4.630 millions
Abbott Laboratories4.42%$ 4.420 millions
Grifols Sa4.32%$ 4.321 millions
Biontech Se4.32%$ 4.318 millions
Ufp Technologies Inc 4.08%$ 4.076 millions
Retractable Technologies Inc4.03%$ 4.029 millions
Lantheus Holdings Inc 3.92%$ 3.915 millions
P3 Health Partners Inc 3.81%$ 3.811 millions
Bio rad Laboratories Inc 3.78%$ 3.780 millions
Personalis Inc 3.24%$ 3.244 millions
Seer Inc 3.14%$ 3.144 millions
Agilon Health Inc 3.09%$ 3.087 millions
Zoetis Inc 3.02%$ 3.021 millions
Valneva Se3.00%$ 2.996 millions
Telix Pharmaceuticals Ltd2.65%$ 2.652 millions
Enovis Corp2.64%$ 2.635 millions
Regeneron Pharmaceuticals Inc 2.51%$ 2.510 millions


About Valneva Se Revenue Growth Rates (VALN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Valneva Se (CIK 1836564).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-018808
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Valneva Se’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.